You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name7,9-Dihydro-1h-Purine-2,6,8(3h)-Trione
Accession NumberDB01696  (EXPT03202)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
SaltsNot Available
Brand namesNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS number69-93-2
WeightAverage: 168.1103
Monoisotopic: 168.028340014
Chemical FormulaC5H4N4O3
InChI KeyLEHOTFFKMJEONL-UHFFFAOYSA-N
InChI
InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)
IUPAC Name
2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-trione
SMILES
O=C1NC2=C(N1)C(=O)NC(=O)N2
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassImidazopyrimidines
SubclassPurines and Purine Derivatives
Direct parentXanthines
Alternative parentsPurinones; Pyrimidones; Imidazoles; Polyamines
Substituentspyrimidone; pyrimidine; imidazole; azole; polyamine; organonitrogen compound
Classification descriptionThis compound belongs to the xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Molybdenium Cofactor DeficiencyDiseaseSMP00203
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Purine MetabolismMetabolicSMP00050
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Xanthinuria type IDiseaseSMP00512
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Xanthinuria type IIDiseaseSMP00513
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
Adenosine Deaminase DeficiencyDiseaseSMP00144
AICA-RibosiduriaDiseaseSMP00168
Myoadenylate deaminase deficiencyDiseaseSMP00537
Azathioprine Action PathwayDrug actionSMP00427
Mercaptopurine Action PathwayDrug actionSMP00428
Thioguanine Action PathwayDrug actionSMP00430
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9927
Blood Brain Barrier + 0.9731
Caco-2 permeable - 0.7844
P-glycoprotein substrate Non-substrate 0.5895
P-glycoprotein inhibitor I Non-inhibitor 0.9651
P-glycoprotein inhibitor II Non-inhibitor 0.9967
Renal organic cation transporter Non-inhibitor 0.9391
CYP450 2C9 substrate Non-substrate 0.7785
CYP450 2D6 substrate Non-substrate 0.7666
CYP450 3A4 substrate Non-substrate 0.7568
CYP450 1A2 substrate Non-inhibitor 0.5
CYP450 2C9 substrate Non-inhibitor 0.8924
CYP450 2D6 substrate Non-inhibitor 0.9124
CYP450 2C19 substrate Non-inhibitor 0.8894
CYP450 3A4 substrate Non-inhibitor 0.8512
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.993
Ames test Non AMES toxic 0.8148
Carcinogenicity Non-carcinogens 0.9508
Biodegradation Not ready biodegradable 0.56
Rat acute toxicity 2.0522 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9564
hERG inhibition (predictor II) Non-inhibitor 0.9563
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
water solubility60 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-2.17NAHUM,A & HORVATH,C (1980)
pKa5.4KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility1.76ALOGPS
logP-1.1ALOGPS
logP-1.5ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)7.61ChemAxon
pKa (Strongest Basic)-6.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity45.63 m3·mol-1ChemAxon
Polarizability13.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
SpectraGC-MSMS/MS
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ResourceLink
KEGG CompoundC00366
PubChem Compound1175
PubChem Substance46505972
ChEBI17775
ChEMBL
HETURC
Drug Product Database686042
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Glycogen phosphorylase, liver form

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Glycogen phosphorylase, liver form P06737 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:15